0001209191-20-036047.txt : 20200611 0001209191-20-036047.hdr.sgml : 20200611 20200611183110 ACCESSION NUMBER: 0001209191-20-036047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200609 FILED AS OF DATE: 20200611 DATE AS OF CHANGE: 20200611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McLoughlin Dennis CENTRAL INDEX KEY: 0001752004 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 20958321 MAIL ADDRESS: STREET 1: C/O PACIRA PHARMACEUTICALS, INC. STREET 2: 5 SYLVAN WAY, SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-09 0 0001396814 Pacira BioSciences, Inc. PCRX 0001752004 McLoughlin Dennis C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 Chief Commercial Officer Common Stock 2020-06-09 4 A 0 14000 0.00 A 28898 D Stock Option (Right to Buy) 47.65 2020-06-09 4 A 0 35000 0.00 A 2030-06-09 Common Stock 35000 35000 D Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. /s/ Kristen Williams, Attorney-in-Fact 2020-06-11